Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease worldwide, but effective treatments are still lacking. Metabolic disorders such as iron overload, glycolysis, insulin resistance, lipid dysregulation, and glutaminolysis are found to...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1505117/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590859637358592 |
|---|---|
| author | Wei Xuan Dandan Song Jianghua Hou Xiuping Meng |
| author_facet | Wei Xuan Dandan Song Jianghua Hou Xiuping Meng |
| author_sort | Wei Xuan |
| collection | DOAJ |
| description | Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease worldwide, but effective treatments are still lacking. Metabolic disorders such as iron overload, glycolysis, insulin resistance, lipid dysregulation, and glutaminolysis are found to induce liver senescence and ferroptosis, which are hot topics in the research of MASLD. Recent studies have shown that Hippo–YAP1/TAZ pathway is involved in the regulations of metabolism disorders, senescence, ferroptosis, inflammation, and fibrosis in MASLD, but their complex connections and contrast roles are also reported. In addition, therapeutics based on the Hippo–YAP1/TAZ pathway hold promising for MASLD treatment. In this review, we highlight the regulation and molecular mechanism of the Hippo–YAP1/TAZ pathway in MASLD and summarize potential therapeutic strategies for MASLD by regulating Hippo–YAP1/TAZ pathway. |
| format | Article |
| id | doaj-art-05997c43d48246df9076adc43cf17500 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-05997c43d48246df9076adc43cf175002025-01-23T06:56:01ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011610.3389/fphar.2025.15051171505117Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver diseaseWei Xuan0Dandan Song1Jianghua Hou2Xiuping Meng3Department of Hepatopancreaticobiliary Surgery, China-Japan Union Hospital, Jilin University, Changchun, ChinaDepartment of Clinical Laboratory, Second Hospital of Jilin University, Changchun, ChinaDepartment of Endodontics, Hospital of Stomatology, Jilin University, Changchun, ChinaDepartment of Endodontics, Hospital of Stomatology, Jilin University, Changchun, ChinaMetabolic dysfunction-associated steatotic liver disease (MASLD) has become the most prevalent chronic liver disease worldwide, but effective treatments are still lacking. Metabolic disorders such as iron overload, glycolysis, insulin resistance, lipid dysregulation, and glutaminolysis are found to induce liver senescence and ferroptosis, which are hot topics in the research of MASLD. Recent studies have shown that Hippo–YAP1/TAZ pathway is involved in the regulations of metabolism disorders, senescence, ferroptosis, inflammation, and fibrosis in MASLD, but their complex connections and contrast roles are also reported. In addition, therapeutics based on the Hippo–YAP1/TAZ pathway hold promising for MASLD treatment. In this review, we highlight the regulation and molecular mechanism of the Hippo–YAP1/TAZ pathway in MASLD and summarize potential therapeutic strategies for MASLD by regulating Hippo–YAP1/TAZ pathway.https://www.frontiersin.org/articles/10.3389/fphar.2025.1505117/fullHippo-YAP1/TAZ pathwaymetabolismsenescenceferroptosisinflammationfibrosis |
| spellingShingle | Wei Xuan Dandan Song Jianghua Hou Xiuping Meng Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease Frontiers in Pharmacology Hippo-YAP1/TAZ pathway metabolism senescence ferroptosis inflammation fibrosis |
| title | Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease |
| title_full | Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease |
| title_fullStr | Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease |
| title_full_unstemmed | Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease |
| title_short | Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease |
| title_sort | regulation of hippo yap1 taz pathway in metabolic dysfunction associated steatotic liver disease |
| topic | Hippo-YAP1/TAZ pathway metabolism senescence ferroptosis inflammation fibrosis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1505117/full |
| work_keys_str_mv | AT weixuan regulationofhippoyap1tazpathwayinmetabolicdysfunctionassociatedsteatoticliverdisease AT dandansong regulationofhippoyap1tazpathwayinmetabolicdysfunctionassociatedsteatoticliverdisease AT jianghuahou regulationofhippoyap1tazpathwayinmetabolicdysfunctionassociatedsteatoticliverdisease AT xiupingmeng regulationofhippoyap1tazpathwayinmetabolicdysfunctionassociatedsteatoticliverdisease |